Eisai Azheimer’s Drug Set to Win Japanese Approval, Following US

Eisai Co.’s breakthrough Alzheimer’s disease drug is poised to gain the backing of Japanese regulators after the medicine was fully cleared in the US last month.

A panel that advises Japan’s health ministry recommended approval of Leqembi, according to a government statement Monday. The ministry relies on the expert panel’s review before clearing new medicines and generally follows its recommendations.